




































Special Edition: Junior Commentary 
 https://doi.org/10.47488/dhrp.v3iS1.95 

 

 
 

 
DHR Proceedings ǀ http://dhrproceedings.org 1 2023, Vol. 3 No. S1 1--10 

 

COMMENTARY 

AI-Powered Precision Oncology: 

Computational Insights Redefining 

Therapeutic Landscapes 

 

Adhira Tippur1 
 

1Mathematics and Science Academy at the University of Texas Rio Grande Valley, Edinburg, TX 

 

Received: August 15, 2023 

Accepted for publication: October 25, 2023 

Published: October 27, 2023

Introduction 

Cancer is one of the world’s leading causes 

of deaths creating a worldwide health challenge (1). 

The number of cancer deaths is rising, presenting a 

formidable and concerning challenge in healthcare. 

Cancer involves the uncontrolled proliferation of 

abnormal cells, disrupting the body's normal growth 

regulation. Moreover, the immune system, which 

typically acts as a defense against such abnormalities, 

may falter, leading to the evasion of cancerous cells 

from detection and elimination (1). Among the various 

types of cancer, the most frequently diagnosed ones 

include lung cancer (accounting for 12.7% of cases), 

breast cancer (10.9% of cases), colorectal cancer 

(9.7% of cases), and gastric cancer (7.81% of cases) 

(2). Over the years from 1991 to 2018, cancer-related 

mortality has shown a steady decline of 31%, 

primarily attributed to advancements in early 

detection, treatment, and reductions in smoking (3). 

Despite this positive trend, cancer continues to be a 

significant contributor to global mortality rates. 

Anticipated data for the year 2023 reveals a projected 

1,958,310 new cancer cases, accompanied by 609,820 

cancer-related deaths across the United States (4). 

During the period from 2014 to 2019, prostate cancer 

experienced a concerning annual increase of 3% in 

incidence, leading to the diagnosis of approximately 

99,000 additional cases. Conversely, other cancer 

incidence trends demonstrated a more favorable 

outlook in men when compared to women, further 

emphasizing the importance of ongoing research and 

targeted interventions to address these disparities. 

Additionally, recent findings highlight a concerning 

increase in early onset cancer incidence among 

younger individuals, while overall rates remain stable 

or decline; unfortunately, younger cancer patients are 

often diagnosed at more advanced stages, significantly 

impacting their chances of successful treatment and 

cure (5). Despite significant advancements in cancer 

research and treatment, the disease remains 

challenging to cure completely. Consequently, the 

pressing need for alternative approaches becomes 

paramount, especially to offer effective solutions for 

high-risk patients. Therefore, cancer research will 

undoubtedly remain at the forefront in the years to 

come, driven by a resolute commitment to saving lives 

and pioneering groundbreaking advancements.  

Artificial intelligence (AI) is a dynamic and 

evolving field of research that involves the application 

of computer systems to replicate and simulate human 

intelligence (6). With the aid of advanced algorithms, 

AI strives to emulate cognitive functions, enabling 

computers to analyze data, recognize patterns, make 

decisions, and learn from experiences, much like the 

human mind. Machine learning and deep learning are 

the major constituents of artificial intelligence (Figure 

1). Machine learning represents a fascinating scientific 

discipline centered around the art of computer systems 

learning from data (7). It emerges from the confluence 

of statistics, which delves into deciphering 

relationships from data, and computer science, with its 

core focus on devising efficient computing algorithms. 

The seamless integration of mathematics and 

computer science in machine learning emerges as a 

result of the complex computational intricacies 

required to construct statistical models from extensive 



Special Edition: Junior Commentary 
 https://doi.org/10.47488/dhrp.v3iS1.95 

 

 
 

 
DHR Proceedings ǀ http://dhrproceedings.org 2 2023, Vol. 3 No. S1 1--10 

datasets, which can consist of billions or even trillions 

of data points (8). Deep learning utilizes multi-layered 

computational models to learn data representations 

with multiple levels of abstraction (9). By employing 

the backpropagation algorithm, machines adjust their 

internal parameters, computing representations in each 

layer based on the previous layer's representation (10). 

 
Figure 1: Relationship between artificial 

intelligence (AI), machine learning (ML), and 

deep learning (DL). Created with BioRender.com 

The surge in artificial intelligent systems has 

generated significant interest in their applications 

within the medical domain (11). Recent times have 

witnessed a swift integration of AI into medical 

practices, driven by the goal of augmenting patient 

care through swifter procedures and enhanced 

precision, thereby laying the foundation for elevated 

healthcare standards. This development marks a 

pivotal stride towards healthcare advancement. AI's 

seamless integration into the medical landscape 

encompasses a broad spectrum of informatics 

techniques, spanning from the intricacies of deep 

learning-driven information management to the 

comprehensive oversight of health management 

systems, notably electronic health records (12). This 

comprehensive expansion extends to the domain of 

clinical decision-making, offering valuable guidance 

to physicians, while also embracing the innovative 

deployment of robots to assist both elderly patients 

and attending surgeons. Within this transformative 

framework, machine learning assumes a prominent 

role, actively engaging in the assessment of 

radiological images, pathology slides, and electronic 

medical records (EMR) of patients. This concerted 

endeavor enhances diagnostic and treatment 

paradigms, amplifying physician capabilities, and 

significantly contributing to the overall advancement 

of healthcare quality (13). This paper meticulously 

examines the major applications of artificial 

intelligence in the field of cancer medicine. Ranging 

from its role in imaging enhancement to its prowess in 

predictive analytics, these applications showcase AI's 

multifaceted potential in transforming cancer care. 

Current Challenges in Cancer Care 

Despite remarkable progress in cancer care 

over the years, the field continues to grapple with 

certain challenges that demand attention and 

innovative solutions. These challenges underscore the 

importance of ongoing research and collaborative 

efforts to further enhance cancer treatment and patient 

outcomes.  

The interplay of rapid urbanization, lifestyle 

choices, and rising life expectancy stands as a 

significant driving force behind the changing 

landscape of cancer incidence rates. According to 

GLOBOCAN predictions, the number of cancer cases 

is expected to reach 28.4 million by 2040 (14). 

Globally, female breast cancer has now surpassed lung 

cancer as the most prevalent cancer (11.7%), closely 

followed by lung (11.4%), colorectal (10.0%), prostate 

(7.3%), and stomach (5.6%) cancers. Lung cancer 

stands as the leading cause for death, accounting for 

1.8 million deaths (18%), followed by colorectal 

(9.4%), liver (8.3%), stomach (7.7%), and female 

breast (6.9%) cancers. Among men, lung, prostate, and 

colorectal cancers are the most prevalent, while breast, 

colorectal, and lung cancers are the leading types 

among women. In fact, cancer cases are expected to 

rise significantly in lower-resource settings and 

countries with a low Human Development Index 

(HDI), while the burden decreases with higher 

national HDI levels (15). In many high-income 

countries (HICs), cancer-screening programs like 

mammography for breast cancer, low-dose CT scan 

for lung cancer and colonoscopy for colorectal cancer 

are challenging to implement in low- and middle-

income countries (LMICs) due to limited resources 

and insufficient trained personnel. This calls for the 

development of technology-driven, cost-effective, and 

user-friendly point-of-care screening and diagnostic 

tools (16).  

Cancer immunotherapy is a well-established 

and crucially important approach in the treatment of 

cancer patients. Over the past decade, therapeutic 

advancements in cancer immunotherapy (CIT) have 

swiftly emerged, underscoring the vital interplay 

between the human immune system and cancer. 

However, it is essential to acknowledge that only a 

minority of patients experience sustainable life-

changing survival outcomes. Cancer immunotherapy 

faces several challenges, including uncertainties in 

effectively translating preclinical findings into 

successful clinical applications and identifying the 

best combinations of immune-based therapies 

personalized to each patient's needs (17). Additionally, 



Special Edition: Junior Commentary 
 https://doi.org/10.47488/dhrp.v3iS1.95 

 

 
 

 
DHR Proceedings ǀ http://dhrproceedings.org 3 2023, Vol. 3 No. S1 1--10 

despite substantial advancements, small-molecule 

targeted anti-cancer drugs still confront several 

hurdles, such as low response rates and the 

development of drug resistance (18). Efforts to address 

these challenges are critical to further improve cancer 

treatment outcomes and advancing the frontier of 

cancer care.  

These challenges really highlight the urgent 

need for better treatment and prediction methods in 

cancer care. Therefore, prioritizing AI-driven 

innovative approaches in technology-based, cost-

effective, and user-friendly point-of-care screening 

and diagnostics can bridge cancer care gaps globally. 

Addressing disparities and strategic healthcare 

resource allocation are essential in combating the 

growing burden in vulnerable regions. 

Role of Artificial Intelligence in Cancer Care 

The potential of AI applications is immense, 

as they can enhance clinician decision-making, 

optimize clinical care processes, improve patient 

outcomes, and lead to reduced healthcare costs (19). 

The rapid expansion of artificial intelligence (AI) 

within the healthcare sector has been remarkable over 

the past decade. AI applications have demonstrated 

their potential in transforming healthcare by 

leveraging clinical data to uncover valuable 

information (Figure 2). Through aiding healthcare 

providers in various critical tasks, such as disease 

diagnosis, patient triage, risk analysis, and surgical 

procedures, AI has become an indispensable tool in 

enhancing overall clinical care and patient outcomes 

(20). AI has achieved prominence as a widely adopted 

technology with a diverse array of multifaceted 

applications across various fields–which will be gone 

over in the following paragraphs. AI has rapidly 

become an integral component in various healthcare 

applications, spanning drug discovery, remote patient 

monitoring, medical diagnostics and imaging, risk 

management, wearables, virtual assistants, and 

hospital management (21). Its diverse and ever-

expanding utilization in these areas showcases the 

transformative potential of AI technology in 

revolutionizing the healthcare landscape. As AI 

continues to evolve and intertwine with healthcare 

practices, it holds the promise of enhancing efficiency, 

accuracy, and overall patient care, ushering in a new 

era of medical innovation. 

 

 
Figure 2: Applications of AI in oncology to solve 

healthcare issues and predict optimal treatment 

outcomes. Created with BioRender.com 

Cancer Imaging and Diagnosis 

AI's remarkable ability to identify intricate 

patterns in medical images revolutionizes image 

interpretation, making it a quantifiable and 

reproducible process. Additionally, AI uncovers 

information imperceptible to human eyes, enhancing 

clinical decision-making (22). Conventional machine 

learning and deep learning techniques are used for 

lesion detection and classification, aiming to reduce 

reading time and enhance accuracy in differentiating 

between benign and malignant cases (23). By 

integrating diverse data streams, including 

radiographic images, genomics, pathology, electronic 

health records, and social networks, AI empowers the 

development of powerful diagnostic systems with far-

reaching potential. Advancements in computer 

programs have led to the development and approval of 

clinical tools such as computer-aided detection (CAD) 

or computer-assisted detection, assisting radiologists 

in detecting potential abnormalities on diagnostic 

radiology exams, thereby reducing false negative rates 

(24). By incorporating CAD into clinical practice, the 

accuracy and reliability of diagnostic radiology are 

enhanced, leading to improved patient outcomes and 

more effective care. Radiology traditionally relies on 

skilled physicians' visual assessments, but this 

approach can be subjective, influenced by their 

education and experience. In contrast, AI excels in 

recognizing intricate patterns within imaging data, 

enabling an objective and automated quantitative 

assessment (21). Integrating AI as a supportive tool 

enhances radiology assessments, advancing patient 

care and outcomes. This collaborative approach, 

combining human expertise and AI-driven precision, 

elevates radiological practices to new heights of 

efficiency and effectiveness (25). As AI continues to 

evolve in radiology, its role as an invaluable ally in 

disease detection, characterization, and monitoring 

becomes increasingly evident, promising a future of 



Special Edition: Junior Commentary 
 https://doi.org/10.47488/dhrp.v3iS1.95 

 

 
 

 
DHR Proceedings ǀ http://dhrproceedings.org 4 2023, Vol. 3 No. S1 1--10 

precision and excellence in medical imaging and 

diagnosis. 

Artificial Intelligence-Driven Precision Medicine 

The integration of artificial intelligence (AI) 

and precision medicine stands poised to catalyze a 

profound transformation within the healthcare 

landscape. Precision medicine introduces a paradigm 

shift, aiming to advance the healthcare model where 

diagnostics, prevention, and treatment strategies are 

meticulously tailored to an individual's unique genetic, 

environmental, and lifestyle attributes (26). This 

approach is instrumental in discerning distinctive 

patient phenotypes marked by uncommon treatment 

responses and specific healthcare requirements. 

Leveraging intricate computational capabilities, AI 

serves as a catalyst, enabling sophisticated reasoning, 

learning, and augmented intelligence, thus 

empowering clinical decision-makers to navigate 

complex healthcare scenarios and deliver personalized 

care with heightened efficacy. The discovery potential 

inherent in precision medicine augments our 

understanding of unexplored therapeutic avenues, 

extending the boundaries of healthcare possibilities 

(27). Critical to the personalization of medical care are 

the diverse data collection and analytical technologies 

that underpin precision medicine's core principles 

(28). Real-time treatment recommendations hinge 

upon the precision of machine-learning algorithms 

that anticipate patients' potential medication 

requirements based on their genomic profiles. At the 

heart of tailored drug administration lies preemptive 

patient genotyping, ensuring optimal therapeutic 

interventions (29). This paradigm underscores a 

seminal example of AI and precision medicine 

synergy, manifesting in the seamless convergence of 

AI techniques with the meticulous interpretation of 

high-throughput genomic data (30).  

Predictive Analytics and Prognosis 

Artificial Intelligence (AI) is increasingly 

utilized to develop cancer prediction models (31). 

Various methods, including statistical, machine 

learning, and deep learning approaches, have been 

employed to enhance prediction accuracy (32-33). 

Machine Learning (ML) algorithms can leverage 

extensive screening data to develop robust models that 

can predict drug responses in cancer patients (34). The 

incorporation of various data types demands more 

resources than analyzing individual data types alone, 

requiring modeling algorithms capable of 

comprehending vast amounts of intricate features (35). 

As a result, AI-driven algorithms are increasingly 

employed to automate cancer prediction by identifying 

the development of cancer and even characterizing it 

(36). A study that was conducted showed the 

proficiency of these machine-learning approaches in 

cancer prediction (36). In this study, differences in 

clinicopathological characteristics were observed 

between the two datasets, with a specific dataset 

showing superior survival rates. In predicting 5-year 

survival, the machine learning model employing light 

gradient boosting surpassed conventional staging 

methods. Notably, age, examined lymph nodes, and 

tumor size emerged as pivotal factors shaping the 

model's performance. The validation set further 

provided sensitivity and positive predictive values for 

survival prediction. This underscores the ML-based 

model's remarkable advancement, surpassing 

conventional staging techniques in providing highly 

precise individualized survival estimations (37). In 

addition to machine learning techniques, two primary 

factors contribute to the attractiveness of deep learning 

in computational biology (38). First and foremost, this 

potent model class has the capacity to approximate 

virtually any input-to-output mapping with sufficient 

data. For instance, when predicting transcription factor 

binding locations, there is no necessity to confine the 

model's expressivity to a single sequence motif (39). 

Notably, deep learning models have been harnessed 

for prediction purposes in a conducted study (40). A 

deep learning model (DeepDR) was made to forecast 

drug responses in cancer cells and tumors. DeepDR 

seamlessly integrates mutation and expression data, 

comprising three pivotal components: one for 

mutation comprehension, another for expression 

analysis, and a final component for drug response 

prediction. Its predictive prowess extends to 265 

drugs, envisaging their efficacy grounded in genetic 

and expression profiles. Rigorously tested on 622 

cancer cell lines, DeepDR showcased remarkable 

performance, surpassing existing methods in drug 

response prediction. Demonstrating its breadth, the 

model further predicted drug responses across 9059 

tumors spanning 33 cancer types. In doing so, it 

unveiled known efficacious drugs and unearthed novel 

candidates, shedding light on drug mechanisms, 

resistance patterns, and proposing a promising 

therapeutic avenue for gliomas and blood cancers. 

Drug Discovery and Development 

Artificial intelligence (AI) presents a 

transformative potential in reshaping both drug design 

strategies and patient treatment paradigms. The 

challenges encompassing drug design, including time 

constraints, production costs, inefficient target 

delivery, and imprecise dosing, have propelled the 



Special Edition: Junior Commentary 
 https://doi.org/10.47488/dhrp.v3iS1.95 

 

 
 

 
DHR Proceedings ǀ http://dhrproceedings.org 5 2023, Vol. 3 No. S1 1--10 

exploration of AI-driven solutions (41). Traditional 

drug development barriers, underscored by intricacies 

in big data handling, have found resolution through AI 

integration, transcending conventional computational 

approaches (42). This synergy has yielded expedited 

drug candidate development, fostering cost-effective 

and structured solutions within notably reduced 

timeframes (43). Complementing this, emerging 

machine learning techniques, notably deep learning, 

have harnessed vast data reservoirs to predict 

molecular structures, in-vivo vs. in-vitro 

characteristics, and outcomes, streamlining drug 

discovery without compromising efficiency (44). AI's 

potential extends to revolutionary platforms like the 

quadratic phenotypic optimization platform (QPOP), 

which, unlike conventional methods, tailors drug 

combinations to specific disease models or patient 

profiles based on empirical data, transcending 

preconceived mechanistic assumptions (45). In 

parallel, AI models, spanning patient stratification, 

pathophysiological casualties, drug candidate design, 

and virtual patient predictions, hold paramount 

significance (46-47). Notably, AI's prowess in 

delineating structure-activity relationships (SAR) and 

exploiting massive sequencing data, such as next-

generation sequencing (NGS), illuminates novel drug 

target identification, augmenting drug discovery 

pathways (48). Within the AI arsenal, artificial neural 

networks, deep neural networks, support vector 

machines, classification and regression techniques, 

generative adversarial networks, symbolic learning, 

and meta-learning algorithms have been harnessed to 

elevate drug design and discovery (49). The 

culmination of individual patient attributes and 

extensive drug candidate predictions within these 

models fosters a new era of personalized and 

optimized treatment strategies, revolutionizing disease 

management practices (50-51). As AI continues to 

reshape drug design and patient-oriented approaches, 

the potential for personalized and precision medicine 

stands poised for unprecedented advancement. 

Challenges and Limitations of Artificial 

Intelligence in Cancer Care 

While AI holds promise in bolstering the 

healthcare sector and improving cancer care, 

apprehensions arise about the potential difficulty in 

validating and questioning AI-mediated decisions, 

which might lead to unconventional outcomes (52). 

The instances of AI integration in healthcare serve as 

pivotal examples, highlighting the significance of 

assessing both the benefits and risks associated with 

emerging AI-driven systems (53). The primary hurdle 

in advancing clinical AI applications in oncology, and 

healthcare in general, lies in data constraints, 

encompassing both quality and quantity aspects. 

Pertinent challenges encompass data curation, 

aggregation transparency, potential bias, and 

reliability concerns (54). The deployment of deep 

learning in precision oncology faces obstacles such as 

scarce phenotypically rich data and the imperative for 

more interpretable deep learning models (55). Ethical, 

copyright, transparency, and legal issues, alongside 

the risk of biases, plagiarism, inaccuracies, limited 

knowledge, incorrect citations, and cybersecurity 

vulnerabilities, underscore AI's limitations (56).  

The issues of AI model interpretability, trust, 

reproducibility, and generalizability have garnered 

substantial attention, with growing recognition of 

biases in demographic factors like sex and ethnicity 

(57). For instance, an AI tool for using 129,450 images 

for detecting skin cancer displayed parity with 

dermatologists but faced criticism for 

underrepresentation of darker skin tones, raising 

concerns about reproducibility and applicability (58-

59). Additionally, the meticulous curation and storage 

of data for machine learning models, along with 

evolving data stewardship expectations, further 

complicate AI advancement (60). Fostering AI 

applications in cancer care demands a focus on clinical 

validity, utility, and usability. Achieving this entails a 

patient-centric, clinical decision-oriented approach to 

model development and assessment (61).  

From challenges in training machine learning 

systems to accountability uncertainties, the 

incremental implementation of AI remains complex 

(62). Moreover, physician comprehension of AI's 

potential remains a significant aspect that needs to be 

addressed (63). This domain undoubtedly holds 

immense promise, yet it is marked by notable gaps and 

ambiguities requiring attention. The primary hurdle 

lies not in the rapid technological advancements, 

which continually unveil new application areas, but 

rather in the deficient legal framework. Inadequate 

regulations, coupled with political, ethical, and 

financial intricacies, underscore the challenge (64). 

Hence, a collaborative effort among technologists, 

policymakers, and ethicists becomes paramount. The 

imperative is to establish a robust legal structure that 

guides innovation while upholding ethical norms. This 

harmonious convergence has the potential to unleash 

the realm's possibilities, dissipating uncertainties and 

nurturing responsible advancement. 

 

 



Special Edition: Junior Commentary 
 https://doi.org/10.47488/dhrp.v3iS1.95 

 

 
 

 
DHR Proceedings ǀ http://dhrproceedings.org 6 2023, Vol. 3 No. S1 1--10 

Ethical and Regulatory Considerations 

Artificial intelligence (AI), while 

transforming the medical landscape, raises significant 

ethical considerations. While AI holds potential in 

healthcare, its implementation necessitates careful 

oversight akin to physician conduct. To ensure safe 

utilization and assessment of AI technology, 

regulatory frameworks are imperative, coupled with 

research into its medical capabilities and constraints 

(63). Given that patients interact with physicians 

during vulnerable moments, maintaining sensitivity to 

this fact is crucial (65). Protecting health data, which 

encompasses private patient and caregiver details and 

medical histories, is paramount. Breaches could lead 

to personal repercussions such as bullying, higher 

insurance premiums, and job loss (66-67). Security, 

privacy, and trust are non-negotiable (68). 

AI will not supplant human roles entirely, but 

integration into physicians' routines can be pivotal 

(68). Transitioning towards personalized, evidence-

based patient management warrants rigorous 

evaluations of AI technologies, particularly in cancer 

risk or management scenarios (68). Ethical concerns 

include the opaque nature of AI decisions, its influence 

on patient engagement and shared decision-making, 

and the allocation of responsibility if AI predictions 

falter (69). Other ethical issues encompass informed 

data consent, safety, transparency, algorithmic 

fairness, biases, and data privacy (65). With AI 

gaining prominence in high-stakes contexts, ensuring 

accountable, equitable, and transparent AI design and 

governance is paramount (70). Transparency hinges 

on accessible and comprehensible information (71). 

Further interdisciplinary collaboration and 

research hold potential to markedly enhance patient 

care quality, rebalance clinician workloads, and 

revolutionize medical practice (72). This dynamic 

journey toward ethical AI integration demands 

collective dedication and thoughtful navigation. 

Conclusion and Discussion 

The dynamic landscape of cancer care poses 

challenges that necessitate innovative and 

collaborative solutions. Factors like urbanization, 

shifting lifestyles, and extended longevity contribute 

to changing cancer rates, underlining the urgency of 

targeted interventions and equitable healthcare access. 

The complexities of cancer prevalence across regions 

and demographics further underscore the need for 

tailored approaches and resource allocation. However, 

implementing effective cancer screening and 

diagnostics remains particularly daunting in resource-

constrained settings, emphasizing the demand for 

technology-driven and user-friendly solutions. 

Challenges persist in immunotherapy and targeted 

drug development, requiring solutions for issues such 

as translation and resistance. 

Artificial intelligence (AI) emerges as a 

potent tool to address these challenges and reshape 

cancer care paradigms. Integrating AI-driven 

innovations into point-of-care screening and 

diagnostics has the potential to bridge global cancer 

care gaps, especially in resource-limited regions. 

Beyond diagnosis and treatment, AI enhances 

clinician decision-making, streamlines clinical 

processes, and drives cost reduction. The rapid growth 

of AI across healthcare domains, from drug discovery 

to medical imaging, underscores its transformative 

impact. AI's proficiency in pattern recognition 

catalyzes a revolution in radiology, enhancing precise 

and efficient image interpretation and elevating patient 

care. Moreover, AI's synergy with precision medicine 

introduces a pivotal shift, enabling tailored treatments 

grounded in individual genetic and environmental 

variables. 

Nonetheless, the substantial potential of AI 

must be approached with ethical considerations and 

vigilance. Prioritizing privacy, security, transparency, 

and bias mitigation is pivotal to ensure AI's equitable 

and responsible deployment in healthcare. 

Collaborative efforts among technologists, 

policymakers, and ethicists are essential to establish a 

robust regulatory framework that guides AI innovation 

while upholding ethical norms. Addressing concerns 

about data quality, model interpretability, and 

accountability remains imperative in AI's ongoing 

evolution. 

In light of these prospects and challenges, the 

integration of AI into cancer care holds promise for 

overcoming obstacles and reshaping patient outcomes. 

By harnessing AI's capabilities and fostering 

collaboration, the healthcare community can strive for 

personalized, effective, and ethically sound cancer 

care on a global scale. This transformative journey 

demands a comprehensive approach, uniting 

technological innovation, regulatory diligence, and 

ethical contemplation. As we navigate this path, the 

convergence of AI and cancer care stands as a beacon 

of hope, promising a future marked by enhanced 

patient well-being and advanced medical progress.



Special Edition: Junior Commentary 
 https://doi.org/10.47488/dhrp.v3iS1.95 

 

 
 

 
DHR Proceedings ǀ http://dhrproceedings.org 7 2023, Vol. 3 No. S1 1-10 

References 

1. Yin W, Wang J, Jiang L, James Kang Y. 

Cancer and stem cells. Exp Biol Med 

(Maywood). 2021;246(16):1791-1801. 

doi:10.1177/15353702211005390 

2. Hazafa A, Rehman KU, Jahan N, Jabeen 

Z. The Role of Polyphenol (Flavonoids) 

Compounds in the Treatment of Cancer 

Cells. Nutr Cancer. 2020;72(3):386-

397. 

doi:10.1080/01635581.2019.1637006 

3. Siegel RL, Miller KD, Fuchs HE, Jemal 

A. Cancer Statistics, 2021 [published 

correction appears in CA Cancer J Clin. 

2021 Jul;71(4):359]. CA Cancer J Clin. 

2021;71(1):7-33. 

doi:10.3322/caac.21654 

4. Siegel RL, Miller KD, Wagle NS, Jemal 

A. Cancer statistics, 2023. CA Cancer J 

Clin. 2023;73(1):17-48. 

doi:10.3322/caac.21763 

5. Radkiewicz C, Andersson TM, 

Lagergren J. Reranking cancer mortality 

using years of life lost. JNCI Cancer 

Spectr. 2023;7(3):pkad038. 

doi:10.1093/jncics/pkad038 

6. Shimizu H, Nakayama KI. Artificial 

intelligence in oncology. Cancer Sci. 

2020;111(5):1452-1460. 

doi:10.1111/cas.14377 

7. Choi RY, Coyner AS, Kalpathy-Cramer 

J, Chiang MF, Campbell JP. 

Introduction to Machine Learning, 

Neural Networks, and Deep Learning. 

Transl Vis Sci Technol. 2020;9(2):14. 

Published 2020 Feb 27. 

doi:10.1167/tvst.9.2.14 

8. Deo RC. Machine Learning in 

Medicine. Circulation. 

2015;132(20):1920-1930. 

doi:10.1161/CIRCULATIONAHA.115.

001593 

9. LeCun Y, Bengio Y, Hinton G. Deep 

learning. Nature. 2015;521(7553):436-

444. doi:10.1038/nature14539 

10. Esteva A, Robicquet A, Ramsundar B, et 

al. A guide to deep learning in 

healthcare. Nat Med. 2019;25(1):24-29. 

doi:10.1038/s41591-018-0316-z 

11. Rajpurkar P, Chen E, Banerjee O, Topol 

EJ. AI in health and medicine. Nat Med. 

2022;28(1):31-38. doi:10.1038/s41591-

021-01614-0 

12. Hamet P, Tremblay J. Artificial 

intelligence in medicine. Metabolism. 

2017;69S:S36-S40. 

doi:10.1016/j.metabol.2017.01.011 

13. Mintz Y, Brodie R. Introduction to 

artificial intelligence in medicine. 

Minim Invasive Ther Allied Technol. 

2019;28(2):73-81. 

doi:10.1080/13645706.2019.1575882 

14. Sung H, Ferlay J, Siegel RL, et al. 

Global Cancer Statistics 2020: 

GLOBOCAN Estimates of Incidence 

and Mortality Worldwide for 36 Cancers 

in 185 Countries. CA Cancer J Clin. 

2021;71(3):209-249. 

doi:10.3322/caac.21660 

15. Soerjomataram I, Bray F. Planning for 

tomorrow: global cancer incidence and 

the role of prevention 2020-2070. Nat 

Rev Clin Oncol. 2021;18(10):663-672. 

doi:10.1038/s41571-021-00514-z 

16. Deo SVS, Sharma J, Kumar S. 

GLOBOCAN 2020 Report on Global 

Cancer Burden: Challenges and 

Opportunities for Surgical Oncologists. 

Ann Surg Oncol. 2022;29(11):6497-

6500. doi:10.1245/s10434-022-12151-6 

17. Hegde PS, Chen DS. Top 10 Challenges 

in Cancer Immunotherapy. Immunity. 

2020;52(1):17-35. 

doi:10.1016/j.immuni.2019.12.011 

18. Zhong L, Li Y, Xiong L, et al. Small 

molecules in targeted cancer therapy: 

advances, challenges, and future 

perspectives. Signal Transduct Target 

Ther. 2021;6(1):201. Published 2021 

May 31. doi:10.1038/s41392-021-

00572-w 

19. Yin J, Ngiam KY, Teo HH. Role of 

Artificial Intelligence Applications in 

Real-Life Clinical Practice: Systematic 

Review. J Med Internet Res. 

2021;23(4):e25759. Published 2021 Apr 

22. doi:10.2196/25759 

20. He J, Baxter SL, Xu J, Xu J, Zhou X, 

Zhang K. The practical implementation 

of artificial intelligence technologies in 

medicine. Nat Med. 2019;25(1):30-36. 

doi:10.1038/s41591-018-0307-0 

21. Hosny A, Parmar C, Quackenbush J, 

Schwartz LH, Aerts HJWL. Artificial 



Special Edition: Junior Commentary 
 https://doi.org/10.47488/dhrp.v3iS1.95 

 

 
 

 
DHR Proceedings ǀ http://dhrproceedings.org 8 2023, Vol. 3 No. S1 1-10 

intelligence in radiology. Nat Rev 

Cancer. 2018;18(8):500-510. 

doi:10.1038/s41568-018-0016-5 

22. Bi WL, Hosny A, Schabath MB, et al. 

Artificial intelligence in cancer imaging: 

Clinical challenges and applications. 

CA Cancer J Clin. 2019;69(2):127-157. 

doi:10.3322/caac.21552 

23. Mendes J, Domingues J, Aidos H, 

Garcia N, Matela N. AI in Breast Cancer 

Imaging: A Survey of Different 

Applications. J Imaging. 2022;8(9):228. 

Published 2022 Aug 26. 

doi:10.3390/jimaging8090228 

24. Castellino RA. Computer aided 

detection (CAD): an overview. Cancer 

Imaging. 2005;5(1):17-19. Published 

2005 Aug 23. doi:10.1102/1470-

7330.2005.0018 

25. Aerts HJ. The Potential of Radiomic-

Based Phenotyping in Precision 

Medicine: A Review. JAMA Oncol. 

2016;2(12):1636-1642. 

doi:10.1001/jamaoncol.2016.2631 

26. Aronson SJ, Rehm HL. Building the 

foundation for genomics in precision 

medicine. Nature. 2015;526(7573):336-

342. doi:10.1038/nature15816 

27. Azad RK, Shulaev V. Metabolomics 

technology and bioinformatics for 

precision medicine. Brief Bioinform. 

2019;20(6):1957-1971. 

doi:10.1093/bib/bbx170 

28. Johnson KB, Wei WQ, Weeraratne D, et 

al. Precision Medicine, AI, and the 

Future of Personalized Health Care. Clin 

Transl Sci. 2021;14(1):86-93. 

doi:10.1111/cts.12884 

29. Schildcrout JS, Shi Y, Danciu I, et al. A 

prognostic model based on readily 

available clinical data enriched a pre-

emptive pharmacogenetic testing 

program. J Clin Epidemiol. 

2016;72:107-115. 

doi:10.1016/j.jclinepi.2015.08.028 

30. Deep learning for genomics. Nat Genet. 

2019;51(1):1. doi:10.1038/s41588-018-

0328-0 

31. Swanson K, Wu E, Zhang A, Alizadeh 

AA, Zou J. From patterns to patients: 

Advances in clinical machine learning 

for cancer diagnosis, prognosis, and 

treatment. Cell. 2023;186(8):1772-

1791. doi:10.1016/j.cell.2023.01.035 

32. Kalafi EY, Nor NAM, Taib NA, 

Ganggayah MD, Town C, Dhillon SK. 

Machine Learning and Deep Learning 

Approaches in Breast Cancer Survival 

Prediction Using Clinical Data. Folia 

Biol (Praha). 2019;65(5-6):212-220. 

33. Ganggayah MD, Taib NA, Har YC, Lio 

P, Dhillon SK. Predicting factors for 

survival of breast cancer patients using 

machine learning techniques. BMC Med 

Inform Decis Mak. 2019;19(1):48. 

Published 2019 Mar 22. 

doi:10.1186/s12911-019-0801-4 

34. Baptista D, Ferreira PG, Rocha M. Deep 

learning for drug response prediction in 

cancer. Brief Bioinform. 

2021;22(1):360-379. 

doi:10.1093/bib/bbz171 

35. Libbrecht MW, Noble WS. Machine 

learning applications in genetics and 

genomics. Nat Rev Genet. 

2015;16(6):321-332. 

doi:10.1038/nrg3920 

36. Osman MH, Mohamed RH, Sarhan HM, 

et al. Machine Learning Model for 

Predicting Postoperative Survival of 

Patients with Colorectal Cancer. Cancer 

Res Treat. 2022;54(2):517-524. 

doi:10.4143/crt.2021.206 

37. Skrede OJ, De Raedt S, Kleppe A, et al. 

Deep learning for prediction of 

colorectal cancer outcome: a discovery 

and validation study. Lancet. 

2020;395(10221):350-360. 

doi:10.1016/S0140-6736(19)32998-8 

38. Issa NT, Stathias V, Schürer S, 

Dakshanamurthy S. Machine and deep 

learning approaches for cancer drug 

repurposing. Semin Cancer Biol. 

2021;68:132-142. 

doi:10.1016/j.semcancer.2019.12.011 

39. Jones W, Alasoo K, Fishman D, Parts L. 

Computational biology: deep learning. 

Emerg Top Life Sci. 2017;1(3):257-274. 

doi:10.1042/ETLS20160025 

40. Chiu YC, Chen HH, Zhang T, et al. 

Predicting drug response of tumors from 

integrated genomic profiles by deep 

neural networks [published correction 

appears in BMC Med Genomics. 2019 

Aug 12;12(1):119]. BMC Med 

Genomics. 2019;12(Suppl 1):18. 

Published 2019 Jan 31. 

doi:10.1186/s12920-018-0460-9 

41. Gupta R, Srivastava D, Sahu M, Tiwari 

S, Ambasta RK, Kumar P. Artificial 

intelligence to deep learning: machine 

intelligence approach for drug 



Special Edition: Junior Commentary 
 https://doi.org/10.47488/dhrp.v3iS1.95 

 

 
 

 
DHR Proceedings ǀ http://dhrproceedings.org 9 2023, Vol. 3 No. S1 1-10 

discovery. Mol Divers. 

2021;25(3):1315-1360. 

doi:10.1007/s11030-021-10217-3  

42. Wang L, Alexander CA. Big data 

analytics in medical engineering and 

healthcare: methods, advances and 

challenges. J Med Eng Technol. 

2020;44(6):267-283. 

doi:10.1080/03091902.2020.1769758 

43. Tripathi MK, Nath A, Singh TP, 

Ethayathulla AS, Kaur P. Evolving 

scenario of big data and Artificial 

Intelligence (AI) in drug discovery. Mol 

Divers. 2021;25(3):1439-1460. 

doi:10.1007/s11030-021-10256-w 

44. Zhao L, Ciallella HL, Aleksunes LM, 

Zhu H. Advancing computer-aided drug 

discovery (CADD) by big data and data-

driven machine learning modeling. 

Drug Discov Today. 2020;25(9):1624-

1638. doi:10.1016/j.drudis.2020.07.005 

45. Zhang L, Tan J, Han D, Zhu H. From 

machine learning to deep learning: 

progress in machine intelligence for 

rational drug discovery. Drug Discov 

Today. 2017;22(11):1680-1685. 

doi:10.1016/j.drudis.2017.08.010 

46. Moingeon P. Artificial intelligence-

driven drug development against 

autoimmune diseases. Trends 

Pharmacol Sci. 2023;44(7):411-424. 

doi:10.1016/j.tips.2023.04.005 

47. Workman P, Antolin AA, Al-Lazikani 

B. Transforming cancer drug discovery 

with Big Data and AI. Expert Opin Drug 

Discov. 2019;14(11):1089-1095. 

doi:10.1080/17460441.2019.1637414 

48. Qin D. Next-generation sequencing and 

its clinical application. Cancer Biol 

Med. 2019;16(1):4-10. 

doi:10.20892/j.issn.2095-

3941.2018.0055 

49. Zhu H. Big Data and Artificial 

Intelligence Modeling for Drug 

Discovery. Annu Rev Pharmacol 

Toxicol. 2020;60:573-589. 

doi:10.1146/annurev-pharmtox-

010919-023324 

50. Chopra H, Baig AA, Gautam RK, 

Kamal MA. Application of Artificial 

Intelligence in Drug Discovery. Curr 

Pharm Des. 2022;28(33):2690-2703. 

doi:10.2174/138161282866622060814

1049 

51. Rashid MBMA, Chow EK. Artificial 

Intelligence-Driven Designer Drug 

Combinations: From Drug 

Development to Personalized Medicine. 

SLAS Technol. 2019;24(1):124-125. 

doi:10.1177/2472630318800774 

52. Liyanage H, Liaw ST, Jonnagaddala J, 

et al. Artificial Intelligence in Primary 

Health Care: Perceptions, Issues, and 

Challenges. Yearb Med Inform. 

2019;28(1):41-46. doi:10.1055/s-0039-

1677901 

53. Küster D, Schultz T. Künstliche 

Intelligenz und Ethik im 

Gesundheitswesen – Spagat oder 

Symbiose? [Artificial intelligence and 

ethics in healthcare-balancing act or 

symbiosis?]. Bundesgesundheitsblatt 

Gesundheitsforschung 

Gesundheitsschutz. 2023;66(2):176-

183. doi:10.1007/s00103-022-03653-5 

54. Norgeot B, Quer G, Beaulieu-Jones BK, 

et al. Minimum information about 

clinical artificial intelligence modeling: 

the MI-CLAIM checklist. Nat Med. 

2020;26(9):1320-1324. 

doi:10.1038/s41591-020-1041-y 

55. Tran KA, Kondrashova O, Bradley A, 

Williams ED, Pearson JV, Waddell N. 

Deep learning in cancer diagnosis, 

prognosis and treatment selection. 

Genome Med. 2021;13(1):152. 

Published 2021 Sep 27. 

doi:10.1186/s13073-021-00968-x 

56. Sallam M. ChatGPT Utility in 

Healthcare Education, Research, and 

Practice: Systematic Review on the 

Promising Perspectives and Valid 

Concerns. Healthcare (Basel). 

2023;11(6):887. Published 2023 Mar 

19. doi:10.3390/healthcare11060887 

57. Beam AL, Manrai AK, Ghassemi M. 

Challenges to the Reproducibility of 

Machine Learning Models in Health 

Care. JAMA. 2020;323(4):305-306. 

doi:10.1001/jama.2019.20866 

58. Esteva A, Kuprel B, Novoa RA, et al. 

Dermatologist-level classification of 

skin cancer with deep neural networks 

[published correction appears in Nature. 

2017 Jun 28;546(7660):686]. Nature. 

2017;542(7639):115-118. 

doi:10.1038/nature21056 

59. Zou J, Schiebinger L. AI can be sexist 

and racist - it's time to make it fair. 

Nature. 2018;559(7714):324-326. 

doi:10.1038/d41586-018-05707-8 



Special Edition: Junior Commentary 
 https://doi.org/10.47488/dhrp.v3iS1.95 

 

 
 

 
DHR Proceedings ǀ http://dhrproceedings.org 10 2023, Vol. 3 No. S1 1-10 

60. Wilkinson MD, Dumontier M, 

Aalbersberg IJ, et al. The FAIR Guiding 

Principles for scientific data 

management and stewardship 

[published correction appears in Sci 

Data. 2019 Mar 19;6(1):6]. Sci Data. 

2016;3:160018. Published 2016 Mar 15. 

doi:10.1038/sdata.2016.18 

61. Kann BH, Hosny A, Aerts HJWL. 

Artificial intelligence for clinical 

oncology. Cancer Cell. 2021;39(7):916-

927. doi:10.1016/j.ccell.2021.04.002 

62. Chomutare T, Tejedor M, Svenning TO, 

et al. Artificial Intelligence 

Implementation in Healthcare: A 

Theory-Based Scoping Review of 

Barriers and Facilitators. Int J Environ 

Res Public Health. 2022;19(23):16359. 

Published 2022 Dec 6. 

doi:10.3390/ijerph192316359 

63. Aung YYM, Wong DCS, Ting DSW. 

The promise of artificial intelligence: a 

review of the opportunities and 

challenges of artificial intelligence in 

healthcare. Br Med Bull. 2021;139(1):4-

15. doi:10.1093/bmb/ldab016 

64. Pashkov VM, Harkusha AO, Harkusha 

YO. ARTIFICIAL INTELLIGENCE IN 

MEDICAL PRACTICE: 

REGULATIVE ISSUES AND 

PERSPECTIVES. Wiad Lek. 

2020;73(12 cz 2):2722-2727. 

65. Naik N, Hameed BMZ, Shetty DK, et al. 

Legal and Ethical Consideration in 

Artificial Intelligence in Healthcare: 

Who Takes Responsibility?. Front Surg. 

2022;9:862322. Published 2022 Mar 14. 

doi:10.3389/fsurg.2022.862322 

66. Thapa C, Camtepe S. Precision health 

data: Requirements, challenges and 

existing techniques for data security and 

privacy. Comput Biol Med. 

2021;129:104130. 

doi:10.1016/j.compbiomed.2020.10413

0 

67. Sheikh A, Anderson M, Albala S, et al. 

Health information technology and 

digital innovation for national learning 

health and care systems. Lancet Digit 

Health. 2021;3(6):e383-e396. 

doi:10.1016/S2589-7500(21)00005-4 

68. Rompianesi G, Pegoraro F, Ceresa CD, 

Montalti R, Troisi RI. Artificial 

intelligence in the diagnosis and 

management of colorectal cancer liver 

metastases. World J Gastroenterol. 

2022; 28(1):108-122. 

doi:10.3748/wjg.v28.i1.108 

69. Hunter B, Hindocha S, Lee RW. The 

Role of Artificial Intelligence in Early 

Cancer Diagnosis. Cancers (Basel). 

2022;14(6):1524. Published 2022 Mar 

16. doi:10.3390/cancers14061524 

70. Morley J, Machado CCV, Burr C, et al. 

The ethics of AI in health care: A 

mapping review. Soc Sci Med. 

2020;260:113172. 

doi:10.1016/j.socscimed.2020.113172 

71. Char DS, Abràmoff MD, Feudtner C. 

Identifying Ethical Considerations for 

Machine Learning Healthcare 

Applications. Am J Bioeth. 

2020;20(11):7-17. 

doi:10.1080/15265161.2020.1819469 

72. Xu L, Sanders L, Li K, Chow JCL. 

Chatbot for Health Care and Oncology 

Applications Using Artificial 

Intelligence and Machine Learning: 

Systematic Review. JMIR Cancer. 

2021;7(4):e27850. Published 2021 Nov 

29. doi:10.2196/27850 

 

 

 

 

 

 


